PT  - JOURNAL ARTICLE
AU  - Dines, Jennifer N.
AU  - Manley, Thomas J.
AU  - Svejnoha, Emily
AU  - Simmons, Heidi M.
AU  - Taniguchi, Ruth
AU  - Klinger, Mark
AU  - Baldo, Lance
AU  - Robins, Harlan
TI  - The ImmuneRACE Study: A Prospective Multicohort Study of Immune Response Action to COVID-19 Events with the ImmuneCODE™ Open Access Database
AID  - 10.1101/2020.08.17.20175158
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.17.20175158
4099  - http://medrxiv.org/content/early/2020/08/21/2020.08.17.20175158.1.short
4100  - http://medrxiv.org/content/early/2020/08/21/2020.08.17.20175158.1.full
AB  - Objectives The primary aim of this study is to increase our understanding of the adaptive immune response to the SARS-CoV-2 virus by assaying the peripheral immune repertoire for virus-associated T-cell receptors (TCRs). Secondary aims include identification and characterization of SARS-CoV-2–specific B-cell receptors (BCRs) and monoclonal antibodies (mAbs) generated by antibody-producing cells during and after acute infection.Trial design ImmuneRACE is a prospective, single group, multi-cohort, exploratory study of unselected eligible participants exposed to, infected with, or recovering from SARS-CoV-2.Participants Approximately 1000 individuals, aged 18 to 89 years and residing in 24 different geographic areas within the United States, will be enrolled, primarily using remote telemedicine technologies. Cohorts will be based on clinical history. Cohort 1 will include participants exposed to SARS-CoV-2 within 2 weeks of study entry. Cohort 2 participants will include those clinically diagnosed or with positive laboratory confirmation of active COVID-19 disease. Cohort 3 will comprise participants previously diagnosed with COVID-19 disease who have been deemed recovered based on two consecutive negative tests, clearance by a healthcare professional, or resolution of symptoms related to COVID-19. All participants must be able to communicate with the investigator and understand and comply with the requirements of the study. Protected populations and those who may not safely participate are not eligible for this study.Intervention and comparator Blood samples and nasopharyngeal or oropharyngeal swabs will be collected from participants. Nasopharyngeal or oropharyngeal swabs will be collected by inserting a swab into the nose or throat of the participant. Samples will be shipped frozen or transported refrigerated or at room temperature to Adaptive Biotechnologies for processing, including, but not limited to, testing for coronavirus or other respiratory illnesses, DNA extraction, and TCR analysis. The immunoSEQ assay will be conducted using DNA extracted from blood samples. An electronic questionnaire will be administered to collect information pertaining to the participant’s medical history, symptoms, and diagnostic tests performed for COVID-19 disease. Participants will have the option to undergo additional blood draws and questionnaires over a 2-month period. In collaboration with Microsoft, we will use machine learning and artificial intelligence approaches to construct a classifier based on TCR repertoire data designed to accurately distinguish COVID-19–positive cases from unexposed controls (from the ImmuneCODE database of TCR sequences). A rigorous statistical analysis will be performed to validate the classifier.Main outcomes The main outcomes of this study will include a comparison of disease-specific TCR signatures in patients and controls, identification of the immunodominant antigens that elicit a T-cell response to SARS-CoV-2, risk stratification based on an individual’s immune signature, and determination of immune signatures of patients exposed to SARS-CoV-2 that may allow earlier detection of infection compared to available tests.Trial registration “ImmuneRACE – Immune Response Action to COVID-19 Events (Protocol ADAP-006, version 1.0; 5/8/2020) is registered with the US National Institutes of Health and can be accessed at ClinicalTrials.gov (NCT04494893).Competing Interest StatementJND, TJM, ES, HMS, RT, MK, LB and HR are employees of Adaptive Biotechnologies and have equity ownership. HR additionally has patents and royalties with Adaptive Biotechnologies.Clinical TrialNCT04494893Funding StatementThe study is sponsored by Adaptive Biotechnologies, an immune-driven medicine company, in partnership with Microsoft, who are working together to decode the immune response to COVID-19 and will provide these data freely to researchers around the world. Additional study partners include LabCorp/Covance and Illumina.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ImmuneRACE Study has been approved by the Western Institutional Review Board (reference number 1-1281891-1) on March 17th, 2020. We certify that the trial has received appropriate ethical approval from WIRB as described. All participants will provide informed consent for sample collection and data use.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and updates related to this clinical trial protocol will be curated on ClinicalTrials.gov where the trial has been registered as NCT04494893. Through a collaboration with Microsoft, TCR sequence data resulting from the primary aims of this study will be made publicly available through the open access database ImmuneCODE at www.immunecode.com. https://www.immunecode.com